Fungal  by unknown




EFFICIACY AND FEASIBILITY OF AEROSOLIZED AM-
PHOTERICIN B LIPID COMPLEX (ABLC) THERAPY IN
CASPOFUNGIN BREAKTHROUGH PULMONARY ZY-
GOMYCOSIS
Safdar A*, O’Brien S, Kouri IF; The University of
Texas M.D. Anderson Cancer Center, Houston, USA
BACKGROUND: Mucorales infection has recently
reemerged as a serious complication in oncology
patients. Treatment options for patients intolerant
to amphotericin B (AmB) therapy are severely lim-
ited and uncertain. We present a patient with pul-
monary zygomycosis who had marked intolerance
and nephrotoxicity to polyene-based antifungal
therapy.
CASE: A 61-year-old non-neutropenic man with
refractory CLL presented with febrile productive
cough, and modest respiratory distress. He was re-
ceiving IDEC-152 therapy, a monoclonal antibody to
CD23; 30 months earlier, he underwent allogeneic
non-myeloablative stem cell transplantation from
HLA-identical donor, and 14 months prior to presen-
tation he had received donor lymphocyte infusion
for persistent disease, which was complicated by
skin and gastrointestinal GvHD, which responded
to corticosteroids. He had received caspofungin
(50mg daily, than 3Xweekly) for nearly 7months for
improving probable invasive pulmonary aspergillo-
sis. A right lower lobe (RLL) inﬁltrate with ‘‘halo
sign’’ (Figure 1a) was evaluated with broncholave-
olar lavage (BAL); Pseudallescheria boydii and Rhi-
zomucor spp. were isolated from RLL BAL samples.
Caspofungin was increased to 100mg daily; he re-
sponded favorably and on discharge the dose was
reduced to 50mg daily. Four weeks later, he had
persistent cough, bronchial cast expectorant, and a
new proximal right lower lobe pleural-based lesion
(Figure 1b); the right supra-diaphragmatic Pseu-
dallescheria pneumonia had resolved on caspofun-
gin therapy (Figure 1c). A trial of liposomal AmB
(3mg/kg daily) had to be discontinued due to rapid
rise in serum creatinine (∼1mg/dl). Aerosolized
ABLC (50mg daily) was commenced and was toler-
ated without untoward effects. Three weeks after
inhalation therapy, a signiﬁcant clinical improve-
ment was accompanied by radiographic resolution
(Figure 1d). No recurrence occurred during ﬁve
months on this treatment, despite severe immuno-
suppression.
CONCLUSIONS: Ecchinocandin-pneumocandin ana-
logues have suboptimal efﬁcacy against most
organisms associated with human zygomycosis.
Aerosolized AmB in heart and ABLC in lung trans-
plant recipients has been safe and effective pro-
phylaxis. This case explores the possible role of
aerosolized ABLC in patients with restricted anti-
fungal choices for pulmonary zygomycosis.
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TEA TREE OIL SUSCEPTIBILITY OF YEASTS ISO-
LATED FROM THE MOUTHS OF TERMINALLY ILL
CANCER PATIENTS
Jackson, MS*, Bagg J, Sweeney, MP, Davies AN; Glas-
gow Dental Hospital and School, Glasgow, UK: Uni-
versity of Bristol
Oran fungal infections are common in patients
receiving palliative care for advanced cancer. Re-
cent reports suggest an increasing prevalence of
azole-resistant yeasts in this patient group. Al-
ternative treatment modalities are therefore, re-
quired. One possible novel treatment is tea tree oil
mouthwash.
OBJECTIVE: To determine the in vitro susceptibility
to tea tree oil of yeasts collected from the mouths
of patients with advanced cancer.
METHODS: The susceptibility to tea tree oil (Thurs-
day Plantation, Wellbeing, Birmingham, England.
Pharmaceutical grade.) of 270 isolates of yeasts
from patients with advanced cancer was deter-
mined using a recognized agent diffusion tech-
nique. Candida albicans ATCC 90028 and Candida
glabrata ATCC 90030 were used as control organ-
isms. Of the 270 isolates, 160 were Candida albi-
cans, 51 were Candida glabrata and the remaining
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59 comprised eight other species. Susceptibilities
to itraconazole, ﬂuconazole and voriconazole by
standard NCCLS broth micro dilution were available
for all isolates.
RESULTS: Overall 24% of isolates were not suscep-
tible to ﬂuconazole at standard dosages. Fifteen
percent were resistant to both ﬂuconazole and
itraconazole and many of these isolated had an el-
evated MIC to voriconazole. All of the isolates were
susceptible to 0.5% or lower concentrations of tea
tree oil.
CONCLUSION: These in vitro data suggest that tea
tree oil may be a valuable preparation in the treat-
ment of oral fungal infections in the terminally ill.
A clinical study should now be considered.
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IN VITRO SUSCEPTIBILITY TESTING OF ASPERGILL-
US TO AMPHOTERICIN B: CORRELATIONWITH OUT-
COME OF INITIAL AMPHOTERICIN B THERAPY IN
CANCER PATIENTS WITH INVASIVE ASPERGILLOSIS
Lionakis MS, Lewis RE, Kontoyiannis DP*; The Uni-
versity of Texas M.D. Anderson Cancer Center, Hous-
ton, Texas
OBJECTIVE: Amphotericin B (AMB) treatment failure
in invasive aspergillosis (IA) exceeds 50% (Lin et al.,
CID, 2001). Even though persistent and profound
immunosuppression may account for this subopti-
mal in vivo efﬁcacy of AMB, in vitro AMB resistance
may also underline some failures of AMB treatment.
Few data regarding the association between in vitro
antifungal susceptibility of Aspergillus species and
outcome of initial AMB therapy are available in pa-
tients with IA.
METHODS: We retrospectively evaluated the as-
sociation of in vitro AMB susceptibility (NCCLS
M38-A microdilution method, E-test method)
along with other prognostic factors with fail-
ure of initial AMB therapy in 54 cancer patients
with probable/deﬁnite IA (EORTC/MSG criteria)
(1999—2003). Only patients who received contin-
uous unchanged AMB as monotherapy for >5 days
were evaluable. We excluded cases of polyfungal
pneumonia.
RESULTS: In only 16 episodes of IA (30%) correlation
between in vitro AMB susceptibility and response
to initial AMB treatment could be clearly assessed.
The remaining 38 episodes of IA were excluded from
our analysis for the following reasons: (a) treatment
with a regimen other than AMB (n = 26; itracona-
zole in 7, voriconazole plus caspofungin in 6, inves-
tigational triazole in 5, AMB plus itraconazole in 3,
AMB plus caspofungin in 2, voriconazole in 2, and
caspofungin in 1 case), (b) multiple fungal species
isolated from respiratory specimens (n = 7; multi-
ple Aspergillus spp in 6, Aspergillus and Fusarium
spp in 1 case), (c) treatment for <5 days (n = 5).
Only the need for admission to the intensive care
unit due to IA, but not in vitro AMB susceptibility
testing, was associated with failure of initial AMB
treatment in these 16 patients.
CONCLUSIONS: Correlation of in vitro susceptibility
testing and in vivo outcome of IA is difﬁcult to as-
sess due to the existence of multiple confounding
factors. Large controlled prospective multi-center
studies are needed to validate the role of in vitro
antifungal susceptibility testing in the management
of IA.
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ISOLATION OF OPPORTUNISTIC FUNGI FROM
BRONCHOALVEOLAR LAVAGE OF COMPROMISED
HOSTS IN ISFAHAN, IRAN
Chadeganipour M*, Shadzi S; Mycology & Parasitol-
ogy Dept. Isfahan Med. School, Isfahan, Iran
OBJECTIVE: The immunological responses of com-
promised hosts are weakened by predisposing
factors such as cancer, immune-deﬁciencies, ma-
lignancies, immunosuppressive therapy, irradia-
tion, transplantation, corticosteroid therapy and
acquired immune deﬁciency syndrome (AIDS)
which susceptible individuals to opportunistic in-
fections. The aim of this study was to examine
the incidence of opportunistic fungi in compro-
mised hosts and to evaluate the signiﬁcance of the
ﬁndings.
METHODS: Bronchoalveolar lavage (BAL) specimens
from 325 immunocompromised patients were inves-
tigated for the prevalence of opportunistic fungi.
BAL specimens were obtained by standard broncho-
scopic procedures.
RESULTS: In the direct examination and culture of
the specimens 5 (2.2%) of ﬁlamentous fungi and 55
(22.2%) yeasts were isolated and identiﬁed as fol-
lows: Aspergillus fumigatus 2, A. terreus 1, A. nidu-
lans 1,Mucor sp. 1, Candida albicans 29, C. glabrata
3, C. parapsilosis 1, Trichosporon beigelli 1, Can-
dida sp. 13 and unknown yeasts 8 cases. In addition,
one strain of Nocardia asteroids and two strains
of Streptomyces somaliansis were isolated. To the
best of our knowledge, there is no previous report
regarding the respiratory infection due to A. ter-
reus and A. nidulans in immunocompromised hosts
in Iran.
CONCLUSION: Evidence obtained from the present
study indicates that opportunistic fungal infection
of the immuno-compromised hosts are becoming
more common in Iran and that any organism should




EFFICACY OF AMPHOTERICIN B LIPID COMPLEX
ALONE AND IN 2-DRUG COMBINATION WITH
CASPOFUNGIN AGAINST ASPERGILLUS FUMIGATUS
IN A MURINE PULMONARY ASPERGILLOSIS MODEL
Chandrasekar PH*, Cutright JL, Manavathu EK;
Wayne State University, Detroit, Michigan, USA
In vitro susceptibility studies have previously shown
that amphotericin B lipid complex (ABLC) in combi-
nation with an echinocandin is synergic against As-
pergillus fumigatus. We therefore investigated the
in vivo efﬁcacy of ABLC alone and in combination
with caspofungin (CFG) against A. fumigatus in-
fection in a murine pulmonary aspergillosis model.
Complement component C’5-deﬁcient DBA/2J fe-
male mice (Jackson Laboratories, Bar Harbor,
Maine) weighing 20—23 grams (6 weeks old) were
made neutropenic by 3 successive intraperitoneal
(i.p.) injections (0.2ml/dose) of cyclophosphamide
(100mg/kg/dose) on days −3, −1 and 1 where day
0 is the day of infection. The neutropenic mice
were anaesthetized by exposing to ether (Sigma
Chemical Company, St. Louis, MO) in a desiccator
for 45± 5 seconds and infected with 1× 106 A.
fumigatus W73355 conidia (0.02ml) delivered to
the nares of the animals from a micropipet. Anti-
fungal drug treatment (ABLC 2.5mg/kg/day; ABLC
5mg/kg/day; CFG 1mg/kg/day; CFG 2mg/kg/day;
ABLC 2.5mg/kg/day + CFG 1mg/kg/day; ABLC
5mg/kg/day + CFG 2mg/kg/day) was initiated
(i.p.) on day 0 and continued for 7 days. The con-
trol animals were treated with PBS. The efﬁcacy of
therapy with ABLC, CFG or ABLC + CFG was evalu-
ated by the effect on fungal burden in the lungs of
infected animals. A comparison of the fungal bur-
den (CFU/lungs) of the animals treated with ABLC,
CFG or ABLC + CFG with that obtained for the
control animals (7495± 4501 CFU/lungs) showed
that ABLC 2.5 + CFG 1 (3775± 3380 CFU/lungs;
p = 0.051) and ABLC 5 + CFG 2 (3010± 4434
CFU/lungs; p = 0.0003) treatment reduced the
fungal burden signiﬁcantly more than that obtained
with controls. These results suggest that a combi-
nation of ABLC with the echinocandin CFG is very
effective in reducing the fungal load in the lungs
of animals suffering from pulmonary aspergillosis.
092
EMERGING RESISTANCE IN YEASTS, COST IMPLICA-
TIONS OF NEWER ANTIFUNGALS AND A RATIONAL
APPROACH TO OPTIMAL ANTIFUNGAL PRESCRIB-
ING IN COMPROMISED HOST–—A TERTIARY HOSPI-
TAL EXPERIENCE
Guleri A*, Alcock SR, Corcoran GD, Speeken-
brink ABJ, Shankland GS; Western Inﬁrmary,
North Glasgow University Hospitals, Glasgow,
UK
OBJECTIVES: Nosocomial candidaemia accounts for
majority of opportunistic fungal infections in com-
promised host, and associated morbidity and mor-
tality. Newer available antifungal drugs (ambisome,
abelcet, caspofungin and voriconazole) offer alter-
native therapeutic options against ﬂuconazole re-
sistant yeasts but have added cost implications. This
clinical audit is an attempt at establishing a ratio-
nal approach to optimal antifungal prescribing.
METHODS: 8-year data (renal transplant, oncology,
ITU/HDU and haematology units) of blood culture
yeast isolates (distribution of candida species and
antifungal susceptibility (NCCLS) proﬁles - AFST)
1. Cost of antifungals per week at standard dosage.
RESULTS: Of 83 yeast isolates Candida albicans
(51.8%) was commonest, C. parapsilosis and C.
glabrata (20.5% each), C. krusei, C. kefyr, C. trop-
icalis, Saccharomyces cerevisiae (1.2% each). All
isolates were sensitive to amphotericin B. Sensi-
tivity to ﬂuconazole and itraconazole respectively:
candida species overall (74.7% and 81.9%), C. al-
bicans (90.7% and 95.3%), C. glabrata (23.5% and
35.3%), C. parapsilosis (94% each) and C. krusei
(0% each). Distribution of candida species and sus-
ceptibility proﬁles in the 4 high-risk units are quite
variable and are discussed.
1. Costs of antifungals (standard dosage/week) vary
from £18 to £4017.00.
CONCLUSIONS: Candidaemia with C. albicans pre-
dominates. In newly diagnosed candidaemia the
likelihood of isolating candida species other than
C. albicans is nearly 50%. Pending identiﬁcation
and AFST (which may take some days), treatment
with amphotericin B deoxycholate, ambisome,
abelcet, caspofungin or voriconazole are options.
Patient risk stratiﬁcation, local epidemiology and
more rapid diagnostic tests (e.g. FISH, E-tests,
automated technology) are discussed.
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EFFICACY OF AMBISOME® AND MICAFUNGIN USED
IN COMBINATION FOR TREATMENT OF SYSTEMIC
CANDIDA GLABRATA INFECTION IN IMMUNOSUP-
PRESSED MICE
Olson JA*, Constable DS, Adler-Moore JP; California
State Polytechnic University, Pomona, CA, USA
OBJECTIVE: Systemic infections with non-albicans
Candida species, such as C. glabrata, havemarkedly
increased during the past decade in immunosup-
pressed patients. These species are often resistant
to azole therapy but are susceptible to polyenes or
echinocandins which target to the fungal membrane
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or cell wall, respectively. Since these agents have
different modes of action, we investigated the ef-
ﬁcacy of combining the polyene, AmBisome (AmBi)
with the echinocandin, Micafungin (Mica) in a sys-
temic immunosuppressed C. glabrata mouse infec-
tion model.
METHODS: C57Bl/6 mice were immunosuppressed
ip with cyclophos-phamide (100mg/kg) every
third day, beginning d-3. Mice were injected iv
d0 with 7.23 Log10 CFU C. glabrata and given iv
monotherapy (n = 7/group) with 7.5mg/kg AmBi
or 2.5mg/kg Mica for d1—3; control mice received
iv 5% dextrose. Another group was given 7.5mg/kg
AmBi as iv prophylaxis on d-7,-5,-3. For sequen-
tial therapy, AmBi (7.5mg/kg) was given on d1—3
followed by Mica (2.5mg/kg) on d4—6, or Mica
(2.5mg/kg) on d1—3 followed by AmBi (7.5mg/kg)
on d4—6. Other groups were given AmBi (7.5mg/kg)
and Mica (2.5mg/kg) together on d1—3 or d1—6.
Mice were sacriﬁced d21 and their kidneys ho-
mogenized, diluted and plated on Sabouraud’s
agar for determination of Log10 CFU/g kidneys
(CFU).
RESULTS: Compared to controls (CFU 5.35),
monotherapy d1—3 with AmBi or Mica were compa-
rable with a reduction in CFU of less than one log
(CFU 4.65 for AmBi and CFU 4.80 for Mica) while
three prophylactic treatments with AmBi (CFU
2.52) was signiﬁcantly better than monotherapy
with either AmBi (p = 0.007) or Mica (p = 0.004).
Sequential therapy with Mica d1—3 followed by
AmBi d4—6 (CFU 3.58), or AmBi d1—3 followed
by Mica d4—6 (CFU 4.34), was signiﬁcantly more
effective than the control (p < 0.038) but not sig-
niﬁcantly different from one another (p = 0.13).
The most efﬁcacious treatment was simultaneous
administration of AmBi and Mica for 3 days (CFU
1.90) or 6 days (CFU 0.97) (p = 0.0006 compared
to control and p < 0.038 compared to sequential
treatments).
CONCLUSIONS: In this mouse model of C. glabrata
infection, monotherapy with AmBi or Mica for 3 days
was not as effective as prophylactic therapy with
AmBi alone or combination treatment with AmBi
andMica. The data showed that AmBi andMica given
together for 3 or 6 days post-challenge could sig-
niﬁcantly improve the outcome in this non-albicans
Candida infection.
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SUCCESSFUL TREATMENT OF FLUCONAZOLE-
RESISTANT CANDIDA SP. CAUSING FUNGUS BALLS
OBSTRUCTING URETER STENTS AFTER RENAL
TRANSPLANTATION
Arend SM*, Kuijper EJ, de Vaal JB, de Fijter JW,
van’t Wout JW; Depts. of Infectious Diseases, Medi-
cal Microbiology and Nephrology, Leiden University
Medical Center, Leiden, The Netherlands
BACKGROUND: Prolonged suppressive treatment
with ﬂuconazole for recurrent Candida albicans
infections carries the risk of secondary resistance
or selection of resistant strains, especially in the
presence of a foreign body. Caspofungin is an
echinocandin that is effective for the treatment
of ﬂuconazole-resistant Candida spp., but con-
centrations in the urine are low (1.4% of plasma
concentration) limiting it’s use in the treatment of
urinary tract infections.
CASE REPORT: A 72-year-old man with autoso-
mal dominant polycystic kidney disease received
a cadaveric kidney transplant in 1996. Recurrent
stenosis of the ureter required sequential implan-
tation of three nonremovable stents between 2000
and 2002. He used ﬂuconazole continuously since
2000 for recurrent urinary tract infections with
C. albicans. In 2003, he was admitted with anuria
and fever, caused by complete obstruction of the
stented ureter and fungus balls in the pyelum.
Fluconazole-resistant C. non-albicans was grown
(MIC > 256g/ml). Phenotypical analysis revealed
Candida sake (ATB 32C, Biomerieux). Treatment
consisted of pyelostomy, intravenous caspofungin
and local irrigation of the pyelumwith Amfotericine
B, later with caspofungin. This resulted in relieve
of the obstruction. As caspofungin cannot be used
orally, prolonged suppressive treatment with this
drug was not an option. In order to cure the in-
fection, removal of all stents would implicate loss
of the ureter while the patient’s own kidneys had
previously been removed precluding the use of an
autologous ureter for reconstruction. One month
after admission, the ureter and all stents were
surgically removed and a cysto-pyelostomy was
created. Perioperatively, 5-ﬂucytosine was given
and caspofungin was continued until 2 weeks after
operation. This resulted in complete cure of the
infection.
CONCLUSION: This patient illustrates that a com-
bined surgical and medical approach including
local and systemic administration of caspofungin
and removal of all foreign material may erad-
icate complicated urinary tract infection with
ﬂuconazole-resistant Candida species.
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COMPARING EPIDEMIOLOGYOF NOSOCOMIAL CAN-
DIDAEMIA IN COMPROMISED HOST AT 3 TERTIARY
CARE HOSPITALS IN UK
Sharma R*1, Neal T1, Grifﬁth P1, Guleri A2; 1Royal
Liverpool University Hospital; 2Western Inﬁrmary,
Glasgow
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BACKGROUND: Nosocomial candidaemia is a signif-
icant cause of morbidity and mortality in compro-
mised critically ill patients. Reduced ﬂuconazole
susceptibility in candida species is widely reported.
This study was undertaken to compare the local epi-
demiology of nosocomial candidaemia in compro-
mised patients at three tertiary referral hospitals of
United Kingdom (Bristol Royal Inﬁrmary (BRI), Royal
Liverpool University Hospital (RLUH), Western in-
ﬁrmary/Gartnavel General Hospital Glasgow (WIG)
and the effect of the local antifungal prescribing
practice.
METHODS: 4-year (Jan 2000—04) data of blood cul-
ture yeast isolates with antifungal susceptibility
proﬁles from high-risk areas (ITU, HDU, Neonatal
intensive care unit & Haematology) in RLUH, BRI
and WIG.
RESULTS: The comparative results at RLUH, BRI and
WIG respectively were: Total number of blood cul-
ture yeast isolates (86, 37 & 30); Candida albicans
was the commonest (66.2%, 51.2% and 62.6%); C.
parapsilosis (15.1%, 28.2% and 21.6%); C. glabrata
(12.7%, 15.3%, and 13.5%); C. guilliermondii (1.16%,
2.56% and 0%) and C. lusitaniae (1.16%, 2.56% and
0%). All isolates were sensitive to amphotericin B.
Sensitivity to ﬂuconazole was: Overall (89.5%, 100%
and 81.1%); C. albicans (100%, 100% & 91.3%); C.
parapsilosis (100% each) and C. glabrata (18.1%,
100% & 20%). The distribution is discussed in tables.
CONCLUSION: At the three centers - C. albicans
is still the commonest cause of nosocomial candi-
daemia; the likelihood of isolating candida species
other than C. albicans is approximately 40% in newly
diagnosed candidaemia. The distribution & suscep-
tibility proﬁle of Candida species at RLUH is similar
to that at WIG, but is different from BRI. A differ-
ence in the antifungal prescribing practice may be
responsible for this—to be discussed.
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CANNOMYS BADIUS AS A NATURAL ANIMAL HOST
OF PENICLLIUM MARNEFFEI IN INDIA
Gugnani H1, Fisher M2, Paliwal-Johsi A1, Vanit-
tanakom N3; 1Department of Medical Mycology, Val-
labhbhai Patel Chest Institute, University of Delhi,
Delhi, India; 2The Institute of Zoology, Regent’s
Park, London NW1 4 R; 3Department of Microbi-
ology, Faculty of Medicine, Chiang Mai University,
Chiang Mai, Thailand
Penicillium marneffei was recovered from the in-
ternal organs of 10 (9.1%) out of 110 bamboo rats
(Cannomys badius) examined from Manipur State,
an area endemic for penicilliosis marneffei in In-
dia. Identiﬁcation of the isolates was based on a
detailed study of their morphological characteris-
tics, in vitro conversion to ﬁssion yeast form and
exoantigen tests. The present study establishes the
bamboo rat Cannomys badius as a natural host of
P. marneffei in India. None of the 72 rats of other
species, viz. Bandicota bengalensis, Rattus norvegi-
cus, R. rattus, R. niditus and Mus musculus trapped
from bamboo plantations from different areas in
northeast India were found to harbour P. marnef-
fei. Multilocus Microsatellite Typing (MLMT) of the
isolates of P. marneffei revealed four genotypes.
One of these genotypes was identical to that seen
in a human isolate suggesting that either coinfec-
tion from a common source or host-to-host trans-
mission had occurred. None of the 25 soil samples
from the burrows of C. badius, and 10 samples each
of bamboo shoots and leaves, yielded any P. marn-
effei isolate.
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ACCURACY OF THE EORTC/MSG DEFINITIONS FOR
INVASIVE FUNGAL INFECTIONS (IFI)WHENAPPLIED
AT THE BEDSIDE
Donnelly JP*1, Blijlevens NMA1, Van Die CE2, Ver-
weij PE3, De Pauw BE4; 1Departments of Hema-
tology, 2Radiology, 3Medical Microbiology and
4Blood Transfusion and Tissue Immunology Univer-
sity Medical Center St Radboud, Nijmegen, The
Netherlands
OBJECTIVE: to assess the accuracy of the EORTC/
MSG deﬁnitions for IFI when applied at the bedside
during neutropenia.
METHODS: The cases of 46 patients suspected of
having or known to have had an IFI during May 2002
and May 2003 were reviewed retrospectively blindly
and classiﬁed according to the EORTC/MSG crite-
ria. Each case was also assessed to see whether the
deﬁnitive diagnosis agreed with the presumptive di-
agnosis made during neutropenia.
RESULTS & CONCLUSIONS: There was complete
agreement for 32 (70%) of the cases. Of 6 cases
eventually classiﬁed as probable IFI, 4 had been
deﬁned presumptively as possible IFI because of
the lack of mycological evidence at the time. A
further 7 cases deﬁnitively classiﬁed as possible
IFI could not be classiﬁed at the bedside because
there were insufﬁcient clinical signs and symptoms
at the time which only became apparent later. 3
cases could not be classiﬁed deﬁnitively, of which 1
had been assigned probable IFI presumptively and
2 possible IFI.
These results indicate a need to determine when
and how often clinical and mycological inves-
tigations need to be carried out to obtain suf-




MICROARRAY ANALYSIS OF EXPRESSION OF GENES
ENCODING INNATE HOST DEFENSE MOLECULES BY
HUMAN MONOCYTES AGAINST Candida albicans
Kim HS*, Choi E, Lyman CA, Khan J, Roilides E,
Chanock SJ, Walsh TJ; National Cancer Institute,
Bethesda, MD
OBJECTIVE: Invasive candidiasis is a leading cause
of infectiousmorbidity andmortality in hospitalized
patients. Host-pathogen interactions induce a re-
lease of intrinsic host defense molecules by phago-
cytic cells in response to C. albicans. However, the
intricate regulatory pathways and complex expres-
sion proﬁles of the multiple genes mediating the
initial immune responses to C. albicans are not well
understood. We therefore investigated the kinetics
of gene expression by DNA microarray analysis in
human monocytes (hMNCs) infected in vitro by C.
albicans.
METHODS: Elutriated hMNCs from ﬁve normal hu-
man volunteers were incubated with or without C.
albicans (1× 107 hMNCs and C. albicans/well) for
0, 2, 4, 6, 8, 12 and 18 hrs. RNA was extracted and
ampliﬁed before analyzing gene expression proﬁle
on 44,000 human gene chips with an Agilent Tech-
nologies Scanner.
RESULTS: At 0, 2, 4 hrs% phagocytosis was 0%, 40%,
and 69% respectively and >82% thereafter. Candida
albicans induced a burst of increased gene expres-
sion up to 6 hrs followed by a marked decrease of
pro-inﬂammatory cytokines, including TNF-α, IL-1,
and IL-6, and the chemokines IL-8, Groα, Groβ,
MIP1β, and MCP1, were simultaneously highly in-
duced during the ﬁrst 6 hours in parallel with the
rate of phagocytosis. However, Th1 and Th2-related
cytokines and receptors (IL-12, IFN-γ, IL-12R, IL-4R,
TGF-β, and IL-10R) and the chemokines MIG and
IP10 were not signiﬁcantly changed over time. Ex-
pression of several genes with immune functions,
but undeﬁned roles in candidiasis, was also de-
ﬁned. Increased expression of genes encoding HSPs
and transferring receptor may enhance inﬂamma-
tion. Up-regulation of genes encoding adenosine
receptors, MAPKs, suppressor of cytokine signaling
3, metallothioneins, CD80, IL-23, and IL-1RA and
down-regulation of IL-15 and CCR2 may be related
to suppression of inﬂammation.
CONCLUSIONS: Expression of genes in hMNCs varies
critically by pathogen exposure time. Candida
albicans is a potent inducer of proinﬂammatory
cytokines and chemokines as the initial innate im-
mune response, while suppressing T-cell related
genes. Pro- and anti-inﬂammatory signals have re-
ciprocal immunoregulatory effects in response to
C. albicans.
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SUCCESSFUL TREATMENT OF RHINOCEREBRAL
MUCORMYCOSIS WITH AMBISOME, SURGICAL DE-
BRIDEMENT AND HYPERBARIC OXYGEN
Skiada A*1, Tofas P1, Papanastasiou K2, Rapidis
AD3, Stamatelou M1, Zachariadis V4, Petrikkos G1;
1Infectious Diseases Research Laboratory, Athens
University, Laikon General Hospital, 2Hematology
Dpt., Ag. Savvas Hospital, 3Dpt. Of Maxillofacial
Surgery, Ag. Savvas Hospital, 4Athens Naval Hospital
32 years old female patient was admitted to the
hospital because of severe thrombocytopenia. Her
past medical history was free. The thrombocytope-
nia was found to be due to underlying myelodysplas-
tic syndrome and treatment with vincristine and
corticosteroids was started. After receiving treat-
ment for about one month the patient developed
swelling and intense pain over the left maxilla. The
symptoms were attributed to dental infection and
amoxicillin was started. Three days later the pa-
tient complained of diplopia. On physical examina-
tion a necrotic eschar was noted on the soft palate.
A biopsy and culture of the lesion revealed infection
by Mucor spp. A CT-scan showed opacity of the left
ethmoid cells and nasal cavity, but no bone erosion.
Treatment with Ambisome was initiated (5mg/kg)
and surgical debridement of the hard palate was
performed. Eight days later an MRI showed that
the lesion extended to the epidural space, form-
ing an epidural abscess. The patient underwent sur-
gical debridement, which included enucleation of
the left eye, resection of the left paranasal sinuses
and partial resection of the left maxilla. Ambisome
was continued at an increased dose (7mg/kg). One
month later and while the patient was still receiv-
ing liposomal amphotericin B, a new necrotic eschar
was noted. Tissue taken for biopsy showed that hy-
phae were still present. Adjunctive treatment with
hyperbaric oxygen was started (total: 70 courses).
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The patient received antifungal treatment for four
and a half months. One year after the initial presen-
tation the patient is well and reconstructive surgery
is planned. This case conﬁrms the existing evidence
that use of all treatment modalities is the best ap-
proach to mucormycosis.
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A CASE OF PERSISTENT CRYPTOCOCCAL MENIN-
GOENCEPHALITIS IN AN IMMUNOCOMPROMISED
PATIENT
Vallianou N, Greka P*, Nicolaou S, Daikos G, Toskas
A, Petrikkos G; 1st Department of Propaedeutic
Medicine, Athens Medical School
A 55 year old male patient was admitted to our
hospital due to severe frontal lobe headache,
vomiting and somnolence that had begun 24 hours
before admission. The patient had a history of
Hodgkins disease treated with MOPP and radiation
therapy ﬁve years ago and was in complete remis-
sion ever since. Fifteen days before his admission
he was diagnosed with diffuse large-B-cell lym-
phoma with bone marrow inﬁltration (stage IV), for
which he was treated with rituximab (anti-CD20)
and CHOP. The last two years he had been re-
ceiving prednisolone (10mg/d) for a vasculitic
rash. Further immunosuppression determinants
were: (i) hypoglobulinaemia (0.4 g/dl), (ii) corti-
costeroid administration (dexamethasone initial
dose 8mg tid) because of focal oedema and (iii)
corticosteroid-dependent diabetes mellitus (during
the last two months of hospitalization). On admis-
sion, the patient was disoriented, confused and had
a temperature of 39 ◦C. Nuchal rigidity and focal
neurologic signs were absent. A lumbar puncture
was performed that showed 75 leucocyte cells/mm3
(90% lymhocytes), while both India ink and culture
were positive for Cryptococcus neoformans var.
neoformans with MICs (g/ml) of 0.25 for ampho-
tericin B, 8 for 5-ﬂucytosine, 8 for ﬂuconazole and
0.125 for voriconazole. Cryptococcal antigen was
detected in CSF and serum in titers of 1:256 and
1:512, respectively. Repeated CSF cytospins along
with brain biopsy were negative for lymphoma
cells. Brain CT revealed a contrast-enhanced area
in the left cerebellum, which was also present
in repeated MRIs that followed together with a
contrast-enhanced area in the left occipital lobe.
The patient received a total of 4.2 g of ampho-
tericin B deoxycholate (D-AMB), 9 g of liposomal
amphotericin as part of combination treatment
with 5-ﬂucytosine (180mg/kg/d) and 17.5mg of in-
trathecally administered (D-AMB). Due to the per-
sistence of the infection (both Indian ink positivity
and rising antibody titers inspite of therapy) he
was also treated with the intravenous voriconazole
formulation (400mg/d) for a total of 20 days (until
his death). The patient died four months after his
admission due to diabetes insipidus attributed to
his meningoengephalitis. This case illustrates the
persistence of cryptococcal CNS infections, espe-
cially in patients with hematologic malignancies,
despite aggressive antifungal chemotherapy.
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ACUTE INFUSION-RELATED REACTIONS (AIRRs)
ASSOCIATED WITH LIPOSOMAL AMPHOTERICIN B
(L-AMB): A REPORT OF TWO CASES
Greka P*, Chrysochoou S, Revenas K, Daikos GL,
Petrikkos GL, Panayiotidis P; 1st Department of
Propedeutic Medicine, Athens University Medical
School
We report the cases of two patients (one male,
60 yrs of age and one female, 26 yrs) that devel-
oped AIRRs immediately after the introduction of
treatment with L-AMB. Both patients were neu-
tropenic as a result of chemotherapy for underlying
hematological malignancies (Acute Myeloblastic
Leukemias) and were eligible for empirical antifun-
gal treatment (prolonged febrile neutropenia un-
responsive to standard antimicrobial combinations
regimens).
Both patients experienced chest pain with ra-
diation to the back, dyspnea, tachycardia, voice
hoarseness and ﬂushing, whereas in one of them
urticarial lesions were also evident. These AIRRs
were noted within the ﬁrst moments of infusion
(approximately ﬁve min, range one to ﬁve). There
was not, synchronous to L-AMB, administration of
other type(s) of medication and no other treat-
ment was initiated that particular day. Patients
had received premedication with paracetamol and
diphenhydramine; the symptoms were unrespon-
sive to slowing of the L-AMB infusion and abated
only after the readministration of diphenydramine
and hydrocortisone. In both patients L-AMB was
thereafter discontinued and treatment with de-
oxycholate AMB (D-AMB) instituted without signs of
AIRRs reccurrence.
In favour of the description of these events as
AIRRs were: (i) the timing of their appearance in
relation to the initiation of the infusion (ii) the
absence of similar reactions in our or other insti-
tutions with drug of the same lot number. None of
these patients had ever been treated either with
D-AMB or L-AMB in the past and furthermore no one
had ever been on medication with liposomal com-
pounds. Each of these patients was also treated
with combinations of the following drugs: antimi-
crobials (mainly -lactams and/or vancomycin),
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proton-pump inhibitors, vitamin K, furosemide,
-blockers, octreotide, calcium gluconate, human
albumin, G-CSF and human recombinant erythro-
poetin.
Literature demonstrates a mean 20% overall fre-
quency of AIRRs in patients treated with L-AMB,
however these two cases were the ﬁrst in our expe-
rience in spite of the fact that L-AMB is a frequently
prescribed drug in our institution where the care of
immunosupressed patients is an every day clinical
practice.
102
EXPERIENCE OF POSACONAZOLE IN PATIENTS
WITH FUSARIOSIS
Raad I*1, Hachem R1, Herbrecht R2, Hare RS3, Cor-
coran G3; 1University of Texas MD Anderson Cancer
Center, Houston, TX, USA; 2Hoˆpital de Hautepierre,
Strasbourg, France; 3Schering-Plough Research In-
stitute, Kenilworth, NJ, USA
OBJECTIVE: Fusarium species have emerged as an
increasingly common cause of human disease that
can manifest as localized or disseminated, life
threatening infections in severely immunocompro-
mised patients. Treating patients with this infec-
tion remains challenging despite the introduction
of new antifungal agents because Fusarium species
are relatively resistant to most therapy. Posacona-
zole is a new oral triazole antifungal agent with
apparent clinical activity against these organisms.
METHODS: This analysis includes patients enrolled
in a large multi-center study of posaconazole
800mg/d administered in divided doses for the
treatment of refractory invasive fungal infections.
All patients had proven or probable infections
caused by Fusarium as a primary pathogen. Data
from these patients were reviewed by an external
data review committee to conﬁrm that EORTC/MSG
criteria for proven or probable infections were
met, and to determine outcomes at the end of
treatment.
RESULTS: Twenty-four patients who enrolled in the
study fulﬁlled the criteria and were included in the
analysis. Patients ranged in age from 10 to 84 years.
Sixteen of 24 patients had a history of hematologi-
cal malignancy, of which half had undergone stem
cell transplantation. Twenty-two of 24 patients had
proven infections. Twelve of 24 patients had dis-
seminated disease, and the other 12 patients had
sites of infection that included lung, eye, sinuses,
skin, bone, and subcutaneous tissue. Fourteen of
24 patients had disease that was refractory to prior
therapy, 4 patients were intolerant of the prior
therapy, and 6 patients did not meet the criteria
for refectory disease or intolerance. Eleven of 24
(45.8%) patients responded positively to therapy,
and 4 of those 11 had disseminated disease. Seven
of the 11 responders were intolerant or had re-
fractory disease. Posaconazole therapy was well
tolerated.
CONCLUSIONS: Infections caused by Fusarium
are associated with a mortality rate higher than
80%; therefore, additional therapeutic options are
needed. These results suggest that oral posacona-
zole may offer a clinically important alternative
for this challenging infection.
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DISTINCT INFLAMMATORY RESPONSES TO LIVE
VERSUS INACTIVATED Aspergillus fumigatus
CONIDIA
Morgan L*, van Epps H, Pamer EG; Infectious Dis-
eases Service, Department of Medicine, Memorial
Sloan Kettering Cancer Center, 1275 York Avenue,
New York, NY 10021
Aspergillus fumigatus, a mold that is prevalent in
the environment, can cause lethal invasive infec-
tions in the immunocompromised host. Infections
with A. fumigatus are acquired by inhalation of
fungal spores or conidia. In healthy, immunologi-
cally intact individuals conidia are rapidly cleared
and inactivated by phagocytic cells of the respi-
ratory tract. In immunocompromised patients, in
particular allogeneic bone marrow transplant re-
cipients, A. fumigatus conidia can germinate and
fungal hyphae can invade the lung parenchyma and
blood vessels and disseminate to other tissues. The
innate immune response plays an essential role
in the control of early fungal infections. In par-
ticular, recruitment of neutrophils and monocytes
and the production of TNF and phagocyte oxidase
are essential for survival of pulmonary infection
with A. fumigatus. To begin to deﬁne the fungal
factors that activate innate immune responses in
the normal host, we characterized the recruitment
of inﬂammatory cells to the lungs of mice inocu-
lated with live A. fumigatus conidia or conidia that
had been inactivated by heat or paraformaldehyde
treatment. We found that intratracheal inoculation
with live conidia resulted in the rapid recruitment
of neutrophils to the lung and air spaces and also
resulted in the production of TNF. In contrast, in-
activated conidia did not induce the recruitment
of inﬂammatory cells or the TNF production. In
vitro studies using bone marrow derived dendritic
cells or RAW264.7 macrophages demonstrated that
live conidia induced rapid secretion of chemokines
KC and Mip-2 while heat inactivated conidia did
not. These results indicate that macrophages and
dendritic cells are able to distinguish between
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live and killed conidia. Live, metabolically ac-
tive conidia induce the production of chemokines
that participate in the recruitment of inﬂamma-
tory cells to the site of infection. The mecha-
nisms underlying this ﬁnding are currently under
investigation.
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CANDIDEMIA AT A LARGE TEACHING HOSPITAL IN
JAPAN
Horiguchi Y1*, Oka Y1, Hashikita G2, Takahashi S2,
Yamazaki T1, Maesaki S1; 1Department of Infec-
tious Disease and Infection Control, Saitama Med-
ical School Hospital; 2Central Clinical Laboratory,
Saitama Medical School Hospital
OBJECTIVE: Blood stream infection due to can-
dida species are becoming increasingly important
causes of morbidity and mortality in hospital-
ized patients. The aim of this study was to ob-
tain epidemiological data on candidemia in pa-
tients at Saitama Medical School Hospital in Japan,
and to discuss the inﬂuence of several clinical
variables on the development and outcome of
candidemia.
MATERIALS & METHODS: Demographic information,
risk factors, therapy and outcome of all patients
who had candidemia at Saitama Medical School Hos-
pital during January 2000 to December 2003 were
reviewed.
RESULTS & CONCLUSIONS: Eighty-four candidemic
episodes were identiﬁed. All the candidemic
episodes were hospital acquired. In this retro-
spective study, the average of annual incidence
of candidemia from 2000 to 2003 was 0.4 cases
per 10,000 patient-days. The most common risk
factors of candidemia were indwelling central
venous catheters (96%) and broad-spectrum an-
tibiotics therapy (87%). Candida albicans was
the most frequently isolated species (52%), fol-
lowed by Candida parapsilosis (24%) and Can-
dida glabrata (14%). A total of 57 (68%) patients
received antifungal treatment after the onset
of candidemia. Fifty-four patients (90%) were
treated with ﬂuconazole, 2 (3%) with ampho-
tericin B. The overall mortality was 46%. Cen-
tral venous catheter related infection, prolonged
hospital stay before the onset of candidemia,
major surgery were signiﬁcantly associated with
poor outcome. Multivariate analysis indicated that
prolonged hospital stay before the onset of can-
didemia (odds ratio, 5.08; 95% conﬁdence inter-
val, 1.83—14.1 central venous catheter related
infection (odds ratio, 0.36; 95% CI, 0.13—0.96)





ENHANCE THE RELEASE OF TUMOR NECROSIS
FACTOR- AND INTERLEUKIN-8 FROM HUMAN
NEUTROPHILS IN RESPONSE TO DIFFERENT ZY-
GOMYCETES
Simitsopoulou M1*, Gil-Lamaignere C1, Maloukou
A1, Walsh TJ2, Roilides E1; 1Aristotle University,
Hippokration Hospital, Thessaloniki, Greece; 2NCI,
NIH, Bethesda MD, USA
OBJECTIVE: Zygomycosis causes increased morbid-
ity and mortality in immunocompromised and dia-
betic patients. Tumor necrosis factor- (TNF-), a
potent pro-inﬂammatory cytokine, and chemokine
interleukin-8 (IL-8) are both regulators of the
antifungal immunity and thus may play a crit-
ical role in host defense against zygomycetes.
We evaluated the effects of interferon- (I)- and
granulocyte-macrophage colony-stimulating factor
(GM) on TNF- and IL-8 release by PMNs against
Rhizopus oryzae (RO), Rhizopus microsporum (RM)
and Absidia corymbifera (AC), three medically
important zygomycetes.
METHODS: PMNs were isolated by dextran sedi-
mentation/ﬁcoll centrifugation from healthy adult
donors. After incubation of PMNs with 100 ng/ml I
alone, GM alone or I + GM together for 2 h (short
incubation) or 22 h (long incubation), untreated
or treated PMNs (1.5× 105/well) were further in-
cubated for 4 h in microtitre plate wells, with or
without hyphae of RO, RM, or AC at an E:T ratio of
10:1. The amounts of TNF- and IL-8 released from
PMNs were then measured in culture supernatants
using ELISA. Statistical analysis was performed by
repeated measures ANOVA with Dunnett post-test
for multiple comparisons.
RESULTS: Treatment with I + GM for 2 h enhanced
TNF- release in response to RM and AC hyphae from
476.6 + 89.3 pg/ml (untreated) to 1222.1+ 236.4
(P < 0.05) and from 391.7 + 118 pg/ml (untreated)
to 848.6+ 285.6 (P < 0.05), respectively. Further,
treatment with I + GM for 22 h enhanced TNF- re-
lease in response to RM hyphae from 354.3+ 77.7
to 905.2+ 192.6 (P < 0.05). By comparison, there
was no signiﬁcant increase of TNF- release after
treatment of PMNs with I alone, GM alone or I + GM
for 2 or 22 h in response to RO hyphae, or after
treatment of PMNs with I alone and GM alone for
2 or 22 h after challenge with RM and AC. In con-
trast, treatment with I alone for 2 and 22 h resulted
in signiﬁcant reduction of IL-8 release (P < 0.01) in
response to all three zygomycetes, while GM alone
stimulated PMNs to increase IL-8 release in response
to AC hyphae (P < 0.01).
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CONCLUSIONS: The combination of I+ GM enhances
the release of TNF- from human PMNs in response
to RM and AC. In contrast, the effects of I and GM on
IL-8 release are more variable. The discortant re-
lease patterns of TNF- and IL-8 achieved by I and
GM suggest differential effects of the two cytokines




UNCOMMON OPPORTUNISTIC INFECTION IN IM-
MUNOCOMPROMISED HOSTS
Morrison VA*; VA Medical Center, Minneapolis MN
Histoplasmosis is an uncommon cause of diarrhea,
even in immunocompromised hosts. We present
a case report of colonic histoplasmosis occuring
in a patient on chronic corticosteroid therapy for
immune thrombocytopenia purpura (ITP). This 78
year old white male presented with a two week
history of abdominal pain and diarrhea. He had had
a similar episode earlier that month, which was
thought to be related to resolving ischemic colitis.
The patient denied any constitutional symptoms,
except for slight anorexia. He had worked as a cab
driver for the past three years, and had not trav-
eled outside of Minnesota over eight years; he had
no pets. The patient had been a farmer until 1941;
since that time, he had had no farm-work expo-
sure. His past medical history was signiﬁcant for
ITP, for which he had been on prednisone, 20mg
daily, for six years. Other chronic medical problems
included COPD and ASCVD. Physical examination
on admission was unremarkable, except for mild
hypotension. Labs were as follows: Hgb 8.5mg/dl,
WBC 5.6× 109/ml, platelet count 350,000, INR
1.01, PTT 29.9, BUN 10, creatinine 1.1mg/dl, total
bilirubin 0.5, alkaline phosphatase 82, AST 18, ALT
21, LDH 595; CXR was normal. Chest/abdominal
CT scan revealed calciﬁcations in multiple lymph
nodes, and multiple 2—3mm bilateral pulmonary
nodules. On colonscopy, multiple polypoid lesions
were seen throughout the colon, with biopsy show-
ing granulomatoid inﬂammation, with collections
in the lamina propria of histiocytes packed with
organisms suggestive of histoplasmosis on PAS
and GMS stains. The biopsy fungal culture grew
Histoplama capsulatum. A bone marrow showed
no evidence of histoplasmosis. The patient was
successfully treated with itraconazole, 200mg po
bid, with his treatment course complicated only
by a GI bleed requiring brief hospitalization. Gas-
trointestinal involvement may be seen in cases of
disseminated histoplasmosis, although manifesta-
tions such as diarrhea, abdominal pain, anorexia,
nausea/vomiting, gastrointestinal bleeding, and
malabsorption are rarely encountered. The ileum
is the most common site of GI involvement. A small
number of GI histoplasmosis cases have been re-
ported from AIDS or lymphoma patients. Deﬁnitive
diagnosis is made by culture identiﬁcation of the
organism. Prolonged antifungal therapy may be
necessary for successful eradication of infection,
especially in immunocompromised patients. As GI
histoplasmosis is uncommon and presenting mani-
festations are nonspeciﬁc, a high index of suspicion
is needed for diagnosis of this infection.
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PEDIATRIC CANDIDEMIA AT KING FAISAL SPECIAL-
IST HOSPITAL AND RESEARCH CENTRE (KFSH&RC),
RIYADH SAUDI ARABIA
Al-Shahrani D, Al Mohsen I*, Al-Abdely H; King Faisal
Specialist Hospital & Research Centre, Riyadh,
Saudi Arabia
OBJECTIVES: To study the epidemiology, risk factors
and outcome in pediatric patients with candidemia
at King Faisal Specialist Hospital and Research Cen-
tre.
METHODS: a retrospective chart review of all pedi-
atric patients with candidemia at KFSH&RC Riyadh,
Saudi Arabia between 1st January 1996 and 31st
December 2000. Data was collected on demograph-
ics, suspected risk factors that included immuno-
suppressive status (primary immunodeﬁciency, im-
munosuppressive drugs, cancer, neutropenia, and
chronic debilitating illnesses), central catheters,
total parenteral nutrition (TPN), antibacterial ther-
apy, ICU stay and mechanical ventilation and other
sites colonization with Candida species.
RESULTS: 94 episodes of candidemia were identiﬁed
in 93 patients, 1 patient had 2 episodes. 56 patients
(60%) were males. C. albicans was the most com-
mon Candida species isolated (57%) followed by C.
parapsillosis (18%), C. tropicalis (14%), C. lucita-
niae (3%) and 1% for Candida krusei, Candida kyfer,
Candida guilliermondi each. The majority of cases
were located at ICUs (38% in Pediatric/cardiac
ICUs, 22% in neonatal ICU) or hematology/oncology
wards (16%). 25 patients (26%) had underlying
hematological malignancies and 20 patients had
cardiac diseases. 16 (17%) of the 93 patients were
new born infants; 40 patients (42.5%) were younger
than 12 months of age, 23 (24.4%) were between 12
and 60 months; and 15 (15.9%) were 5 to 12 years
of age. 28 (29.8%) had major surgery in less than a
month before candidemia. 63 cases (68%) had ICU
admission and 56 (60%) had mechanical ventilation
before candidemia. 85 patients (91%) had central
venous catheter with 52 (56%) on TPN at the time
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of candidemia. The majority of patients had 2 or
more broad-spectrum antibacterials (93.6%) prior
to candidemia. 23 patients (25%) had ANC = 1000
on the day of candidemia. Other site colonization
with Candida species was evident in 28.7%. 51
cases (54%) had fever and 34 (36%) had hypotension
that required inotropic support. Site of culture was
central in 58% of cases. 77 patients (82%) received
therapeutic amphotericin B. Complications were
seen in 9 cases, the most commonly involved or-
gans were liver and spleen. Over all mortality was
24%.
CONCLUSION: Candida is a major of blood stream
infections at KFSH&RC. Candidemia is a life-threat-
ening infection that mainly affects the immune sup-
pressed patients and those with indwelling central
venous catheters with high mortality. Removal of
CVL improve outcome.
